Skip to content

Welcome to Discover Pharma! Today is : October 16, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

ViiV Healthcare

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    ViiV’s Cabenuva achieves superior viral suppression in CROWN Phase 3b study

    ViiV Healthcare’s long-acting HIV treatment Cabenuva achieved superior viral suppression [...]

    October 6, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    FDA approves Tivicay PD for children with HIV weighing at least 2kg

    ViiV Healthcare has received US FDA approval for Tivicay PD [...]

    September 4, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    FDA approves ViiV’s Tivicay PD for young children with HIV

    The FDA has approved ViiV Healthcare’s Tivicay PD for children [...]

    August 26, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    ViiV’s Cabenuva shows superior HIV control to daily oral therapy in adolescents

    ViiV Healthcare’s long-acting injectable Cabenuva has demonstrated superior virologic outcomes [...]

    July 30, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    ViiV Healthcare HIV regimen Dovato non-inferior to Biktarvy in Phase 3b study

    ViiV Healthcare’s two-drug HIV regimen Dovato was non-inferior to the [...]

    July 28, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    ViiV Healthcare gains FDA Priority Review for paediatric Tivicay expansion to newborns

    ViiV Healthcare has secured FDA Priority Review for its application [...]

    June 22, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    ViiV Healthcare reports 12-month data showing lotivibart maintains viral suppression in ultra long-acting HIV regimen

    ViiV Healthcare, the global specialist HIV company majority owned by [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    ViiV Healthcare highlights ultra long-acting HIV pipeline and Phase 1 data at CROI 2026

    ViiV Healthcare will present new data from its long-acting and [...]

    May 5, 2026
  • Drug Delivery & Formulation,Drug Discovery & Development,Opinion & Events

    Most people with HIV choose long-acting injectables over daily pills

    Cabotegravir and rilpivirine long-acting treatment proves highly effective and widely [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Aravax to present Phase 2 peanut allergy data in November
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • CPHI Milan to focus on practical sustainability across pharma supply chains
    Categories: Manufacturing & Supply Chain, Opinion & Events
  • Brenntag and dsm-firmenich agree global GMP vitamin deal
    Categories: Clinical & Regulatory
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top